Metabolic Abnormalities - HIV Infected and Uninfected Males

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
ClinicalTrials.gov Identifier:
NCT00260936
First received: November 30, 2005
Last updated: October 8, 2013
Last verified: August 2013

November 30, 2005
October 8, 2013
March 2006
August 2007   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00260936 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Metabolic Abnormalities - HIV Infected and Uninfected Males
Prevalence of Morphologic and Metabolic Anormalities in HIV Infected and Uninfected Young Men

To assess whether there exist significant differences in glucose metabolism, lipids, lactate, body composition, and bone density between HIV-infected and uninfected young men.

The study involves a one-time collection of health and medical history data, blood and urine specimens, and physical assessments. This study will elucidate the need for a further in-depth study to understand the pathophysiological effects of protease inhibitor (PI)-based and non-nucleoside analogue reverse transcriptase inhibitor (NNRTI)-based therapies in young men.

Observational
Observational Model: Case Control
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample

Approximately 250 subjects will be enrolled in the study. The number of subjects enrolled in each study group will be as follows: 50 HIV-negative subjects; 100 HIV-positive subjects who are antiretroviral therapy (ART) naïve; and two groups of up to 50 HIV-positive subjects each, one on an NNRTI-based regimen and the other on a PI-based regimen.

HIV Infections
Not Provided
  • HIV-negative
    HIV-infected and -uninfected males, ages 12 to 24 years, of Tanner Stage 4 or 5
  • HIV-positive, has never been on ART
    HIV-positive, has never been on ART
  • HIV-positive, non PI containing NNRTI-based regimen
    HIV-positive, currently on a non-PI-containing NNRTI-based regimen for at least 12 weeks. Must never have received a total of more than 6 months of PI-containing regimen, and at least one year must have passed since receipt of last PI-containing regimen
  • HIV-positive, non-NNRTI-containing PI-based regimen
    HIV-positive, currently on a non-NNRTI-containing PI-based regimen for at least 12 weeks. Must never have received a total of more than 6 months of NNRTI-containing regimen, and at least one year must have passed since receipt of last NNRTI-containing regimen.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
250
August 2007
August 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males age 12 years and 0 days through 24 years and 364 days.
  • Tanner stage 4 or 5.
  • Accessible medical history and medications history.
  • Willingness to fast and complete all clinical evaluations and specimen collection.
  • Willingness and ability to give informed consent or assent with parental/legal guardian permission, where required.

Group 1: HIV-Negative Control Subject Specific Inclusion Criteria

  • All subjects for Group 1 will be tested for HIV-1 to confirm negativity unless they have a documented negative antibody test within the last three months of study entry.
  • Willingness and ability to give informed consent for HIV testing. Groups 2, 3, and 4: HIV-Positive Subject Specific Inclusion Criteria
  • HIV-1 infection as documented by a positive result on any of the following licensed tests at any time: any antibody test confirmed by Western blot, HIV culture, plasma HIV-1 RNA PCR >1,000 copies/ml or HIV-1 DNA PCR.
  • Horizontal HIV infection transmission (non-perinatal, non-transfusion acquired infection).
  • Group 2: Currently not on ART and must never have received ART.
  • Group 3: Currently on a NNRTI, non-PI containing regimen for three or more months, must never have received a total of more than six months of PI-containing regimen and at least one year must have passed since receipt of last PI-containing regimen.
  • Group 4: Currently on a PI, non-NNRTI containing regimen for three or more months, must never have received a total of more than six months of NNRTI-containing regimen and at least one year must have passed since receipt of last NNRTI-containing regimen.

Exclusion Criteria:

  • Transgender male to female (MTF) or female to male (FTM) youth
  • Refusal to fast for the 8 hours before collection of laboratory specimen requiring fasting.
  • Unable to obtain medical/medications history.
  • History of anorexia or bulimia.
  • Type I Diabetes Mellitus.
  • Type II Diabetes Mellitus and cannot omit diabetes medication for the 48-hour period prior to laboratory specimen collection for oral glucose tolerance test (OGTT).
  • Current use or use within the past 6 months of oxandrolone, nandrolone, oxymetholone, stanozolol, or any other synthetic anabolic/androgenic agents.
  • Current use or use within the past 6 months of pharmacologic doses of growth hormone. Physiologic growth hormone replacement therapy is permitted, as long as dosages meet the following specifications:
  • Adolescents in puberty - less than or equal to an equivalent of 0.1 mg/kg/day
  • Adolescents past puberty - less than or equal to an equivalent of 0.025 mg/kg/day
  • Current use or use within the past 6 months of pharmacologic doses of testosterone. Physiologic testosterone replacement therapy is permitted as long as dosages meet the following specifications:
  • Injection - no more than 400 mg/month of testosterone enanthate
  • Patch - no more than 5 mg/day (e.g. Testoderm, Androderm)
  • Gel in pre-packaged doses - no more than 7.5 g/day of gel (e.g. Androgel, Testim)
Male
12 Years to 24 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States,   Puerto Rico
 
NCT00260936
ATN 021b
No
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Not Provided
Study Chair: Grace Aldrovandi, MD Children's Hospital Los Angeles
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
August 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP